Intellia Therapeutics (NTLA) Accumulated Depreciation (2015 - 2025)

Intellia Therapeutics (NTLA) has 11 years of Accumulated Depreciation data on file, last reported at $58.6 million in Q4 2025.

• Accumulated Depreciation for Q4 2025 came in at $58.6 million, up 17.94% year-over-year; the trailing twelve-month figure through Dec 2025 was $58.6 million (up 17.94% YoY), and the FY2025 annual result was $58.6 million, up 17.94% from the prior year.
• Accumulated Depreciation rose to $58.6 million in Q4 2025 per NTLA's latest filing, from $49.7 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $58.6 million in Q4 2025 and troughed at $26.1 million in Q4 2021.
• A 5-year average of $41.5 million and a median of $39.9 million in 2023 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2021 and 2025: Accumulated Depreciation jumped 35.09% in 2021, then rose 17.94% in 2025.
• A 5-year view of Accumulated Depreciation shows it stood at $26.1 million in 2021, then advanced by 27.13% to $33.2 million in 2022, then advanced by 20.07% to $39.9 million in 2023, then advanced by 24.66% to $49.7 million in 2024, then climbed by 17.94% to $58.6 million in 2025.
• Business Quant data shows NTLA's Accumulated Depreciation at $58.6 million in Q4 2025, $49.7 million in Q4 2024, and $39.9 million in Q4 2023.